Imugene company info

What does Imugene do?
Imugene (ASX:IMU) is a clinical-stage immuno-oncology company developing oncolytic virotherapies (OV) and T-cell receptor (TCR) therapies for the treatment of cancer. The company's OV platform is designed to selectively infect and replicate within cancer cells, while sparing healthy cells. Imugene's TCR therapy platform is designed to engineer T cells to recognize and kill specific cancer cells.
Imugene company media
Company Snapshot

Is Imugene a public or private company?

key
Ownership
Public

How many people does Imugene employ?

people
Employees
59

What sector is Imugene in?

pie chart
Sector
Health Care

Where is the head office for Imugene?

location pin
Head Office
New South Wales, Australia

What year was Imugene founded?

founded flag
Year Founded
2012
What does Imugene specialise in?
/Biotech /Pharmaceutical /Medical /Health /Healthcare /Treatment /Cancer

What are the products and/or services of Imugene?

Overview of Imugene offerings
Oncolytic virotherapy (OV) CF33: CF33 is a proprietary OV that selectively infects and replicates within cancer cells, while sparing healthy cells. CF33 is currently in Phase 2 clinical trials for the treatment of gastric cancer and head and neck cancer.
Oncolytic virotherapy (OV) VAXINIA: VAXINIA is a proprietary OV that is being developed for the treatment of solid tumors. VAXINIA is currently in Phase 1 clinical trials for the treatment of non-small cell lung cancer.
Oncolytic virotherapy (OV) HER-V: HER-V is a proprietary OV that is being developed for the treatment of breast and gastric cancers. HER-V is currently in Phase 1 clinical trials.
T-cell receptor (TCR) therapy targeting NY-ESO-1: Imugene's TCR therapy targeting NY-ESO-1 is being developed for the treatment of a variety of solid tumors that express NY-ESO-1. Imugene's TCR therapy targeting NY-ESO-1 is currently in Phase 1 clinical trials.
Personalized cancer vaccines: Imugene is developing personalized cancer vaccines that are designed to induce an immune response against the patient's own tumor. Imugene's personalized cancer vaccines are currently in preclinical development.
CAR T-cell therapy: Imugene is developing a CAR T-cell therapy for the treatment of B-cell lymphoma. Imugene's CAR T-cell therapy is currently in preclinical development.

Who is in the executive team of Imugene?

Imugene leadership team
  • Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD
    Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD
    Executive Chairman
  • Ms. Leslie  Chong
    Ms. Leslie Chong
    CEO, MD & Executive Director
  • Mr. Michael  Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD
    Mr. Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD
    CFO & Company Secretary
  • Dr. Nicholas J. Ede B.Sc.(Hons.), Ph.D.
    Dr. Nicholas J. Ede B.Sc.(Hons.), Ph.D.
    Head of Corporate Development
  • Dr. Monil  Shah M.B.A., Pharm.D.
    Dr. Monil Shah M.B.A., Pharm.D.
    Chief Business Officer
  • Dr. Bradley  Glover Ph.D.
    Dr. Bradley Glover Ph.D.
    Chief Operating Officer
  • Ms. Ursula  McCurry
    Ms. Ursula McCurry
    Senior Vice President of Clinical Operations
  • Dr. John  Byon
    Dr. John Byon
    Senior Vice President of Clinical Development